Ind-Swift Labs Q1FY27: EBITDA Up 2.85x to ₹33.32 Cr, Revenue Grows 21.16% YoY
Ind-Swift Laboratories reported a strong Q1FY27 with operational EBITDA up 2.85x YoY to ₹33.32 crore and margins at 17.91%. Standalone revenue grew 21.16% YoY to ₹186.08 crore, with PAT (excl. exceptional items) up 2.04x YoY to ₹24.68 crore. CDMO partnerships and own-brands with Viatris, Manx, and Arrotex are expected to add ₹200-220 crore revenue in FY27. The company projects over 50% revenue growth in FY27.
The substantial year-on-year growth in revenue and profitability, coupled with strategic commercializations and positive future guidance, are material developments that are expected to significantly impact the company's financial performance and market position.
The company reported significant year-on-year growth in key financial metrics such as EBITDA and PAT, along with margin expansion. The successful commercialization of new partnerships and product launches, coupled with positive future outlook and growth projections, indicate a strong positive sentiment.
Ind-Swift Laboratories Limited (ISLL) announced its unaudited financial results for the quarter ended June 30, 2026 (Q1FY27), presenting a strong start to the fiscal year. The company reported a significant improvement in operational EBITDA, which surged 2.85 times year-on-year to ₹33.32 crore, with the operating EBITDA margin expanding by 1,258 basis points to 17.91%. This improvement reflects enhanced efficiencies, a favorable business mix, and disciplined execution.
On a standalone basis, operating income grew by 21.16% year-on-year to ₹186.08 crore. Profit After Tax (PAT), excluding exceptional items, jumped 2.04 times year-on-year to ₹24.68 crore, with the PAT margin improving by 827 basis points to 13.26%.
The company highlighted the commercialization of its CDMO partnerships and own-brands with Viatris (Ireland, Europe), Manx (UK), and Arrotex (Australia). These ventures are expected to contribute an incremental ₹200-220 crore in revenue during FY27. Additionally, two new products, Ibuprofen Sachet for Europe and Macrogol Sachet for the UK and Australia, were launched during the quarter.
Looking ahead, Ind-Swift Laboratories aims to expand its domestic business through high-margin segments like Ethical (76% Gross Margin), Own-Brand (51% GM), and CMO (42% GM). Internationally, the company anticipates FY27 revenue growth of over 50%, with a medium-term revenue CAGR of 20-25% and EBITDA margin expansion of 600-800 basis points, driven by deeper own-brand penetration in the UAE and Central Asia, the Viatris partnership, and continued investment in manufacturing infrastructure, including the Samba EU-GMP upgrade.
What to do with a filing like this
Ind-Swift Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Ind-Swift Laboratories Limited. Read the original for the full detail.